Grants and Contributions:
Title:
Developing Robust Immune-Evasive Hydrogel Capsules for Cell Therapy
Agreement Number:
981387
Agreement Value:
$75,000.00
Agreement Date:
Oct 1, 2021 - Mar 31, 2022
Description:
Cell-based therapies for chronic disorders such as Type 1 Diabetes hold the promise of curative treatments. This project aims to developing robust yet immune-evasive hydrogel capsules to enable islet transplants in a mouse model.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Dundas, Ontario, CA L9H 2E7
Reference Number:
172-2021-2022-Q3-981387
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
735566085
Recipient Type:
For-profit organization
Recipient's Operating Name:
Allarta
Recipient's Legal Name:
Allarta Life Science Inc.
Federal Riding Name:
Hamilton West--Ancaster--Dundas
Federal Riding Number:
35038
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171